World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 10 July 2012
Main ID:  EUCTR2007-004277-26-AT
Date of registration: 21/04/2009
Prospective Registration: Yes
Primary sponsor: Gilead Sciences Inc
Public title: An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebulizer Solution (AZLI) versus Tobramycin Nebulizer Solution (TNS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects with Cystic Fibrosis Followed by an Open-Label, Single-Arm Extension
Scientific title: An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebulizer Solution (AZLI) versus Tobramycin Nebulizer Solution (TNS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects with Cystic Fibrosis Followed by an Open-Label, Single-Arm Extension
Date of first enrolment: 21/01/2010
Target sample size: 273
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004277-26
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no  
Phase: 
Countries of recruitment
Austria Belgium Denmark France Germany Ireland Italy Netherlands
Portugal Spain United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
• Males or females aged 6 years and older
• Patients with CF as diagnosed by one of the following:
• Documented sweat chloride = 60 mEq/L by quantitative pilocarpine iontophoresis test, or
• Documented sweat sodium = 60 mmol/L, or
• Two well characterized genetic mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, or
• Abnormal nasal potential difference with accompanying symptoms characteristic of CF
• Documented PA in an expectorated sputum or throat swab culture within 3 months prior to Visit 1 or at Visit 1
• Patients must be able to provide written informed consent/assent prior to any study related procedures; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure
• Patients must have received previous treatment with aerosolized antibiotics without demonstration of drug intolerance
• FEV1 = 75% predicted at Visit 1
• Ability to perform reproducible pulmonary function tests
• Chest radiograph at Visit 1 without significant acute findings (eg, infiltrates [lobar or diffuse interstitial], pleural effusion, pneumothorax); or chest radiograph or MRI obtained within the 180 days prior to Visit 1 without acute findings and no significant intercurrent illness; chronic, stable findings (eg, chronic scarring or atelectasis) are allowed.

Inclusion criteria for extension phase:
• Subjects must be able to provide written informed consent/assent prior to any study related procedures; parent/guardian must be able to give written informed consent as necessary prior to any study related procedures
• Subjects must have received previous treatment with aerosolized antibiotics without demonstration of drug intolerance
• Completed at least one course of AZLI or TNS during the randomized portion of the study

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
•• Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone a day or 20 mg prednisone every other day
• History of sputum or throat swab culture yielding B. cepacia in the previous 2 years
• Current requirement for daily continuous oxygen supplementation or requirement for more than 2 L/minute at night
• Administration of any investigational drug or device within 28 days of Visit 1 or within 6 half-lives of the investigational drug (whichever is longer)
• Known local or systemic hypersensitivity to monobactam antibiotics
• Known allergies/intolerance to tobramycin
• Inability to tolerate inhalation of a short acting ß2 agonist
• Changes in or initiation of chronic azithromycin treatment within 28 days prior to Visit 1
• Administration of antipseudomonal antibiotics by inhalation, intravenous or oral routes within the 14 days prior to Visit 1
• Changes in antimicrobial, bronchodilator (BD), dornase alfa, or corticosteroid medications within 7 days prior to Visit 1
• Changes in physiotherapy technique or schedule within 7 days prior to Visit 1
• History of lung transplantation
• Abnormal renal or hepatic function or serum chemistry at Visit 1, defined as:
- AST, ALT > 5 times upper limit of normal range (ULN)
- Creatinine > 2 times ULN
• Positive pregnancy test at Visit 1; all women of childbearing potential will be tested
• Female of childbearing potential who is lactating or is not (in the opinion of the investigator) practicing an acceptable method of birth control; female subjects who utilize hormonal contraceptives as one of their birth control methods must have used the same method for at least 3 months before study dosing
• Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment, or compliance with the protocol

Exclusion criteria for extension phase:
• Known local or systemic hypersensitivity to monobactam antibiotics
• Inability to tolerate inhalation of a short acting ß2 agonist
• Positive urine pregnancy test; all women of childbearing potential will be tested
• Female of childbearing potential who is lactating or is not (in the opinion of the investigator) practicing an acceptable method of birth control
• Concurrent participation in a study of another investigational medication or device
• Use of another investigational product (with the exception of AZLI) within the last 28 days
• Terminated early from the randomized portion of the study, but not yet reached the 6 month time point for entry into the AZLI extension phase




Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.
MedDRA version: 9.1 Level: LLT Classification code 10011762 Term: Cystic fibrosis
Intervention(s)

Trade Name: Cayston
Product Name: AZLI
Product Code: AZLI
Pharmaceutical Form: Powder for nebuliser solution
INN or Proposed INN: aztreonam lysine
Current Sponsor code: AZLI
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 75-

Trade Name: TOBI
Pharmaceutical Form: Nebuliser solution
INN or Proposed INN: tobramycin
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-

Primary Outcome(s)
Secondary Objective: • Change from baseline in the Cystic Fibrosis Questionnaire – Revised (CFQ-R) Respiratory Symptoms Scale at Day 28
• Relative change from baseline in FEV1 percent of predicted at Week 20 (end of last treatment course of AZLI or TNS)
• Use of additional (non-protocol specified) antipseudomonal antibiotics during the course of the study
• Hospitalizations during the course of the study
• Change in PA CFUs in sputum at the end of each on-drug cycle
• Changes from baseline in FEV1, FVC and FEF 25-75 at each study visit
• Change from baseline in other domains as assessed by the CFQ-R at each visit
• Changes from baseline in weight and Body Mass Index (BMI) at each visit
• Missed school/work days during the course of the study
Treatment Satisfaction Questionnaire for Medication (TSQM) at Day 28 and either Day 140 or ET

Main Objective: To assess the comparative safety and efficacy of Aztreonam Lysine for Inhalation (AZLI) and Tobramycin Nebuliser Solution (TNS) in adult and pediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.

Primary end point(s): Relative change from baseline in FEV1 percent of predicted at Day 28 among all subjects (non-inferiority analysis) (Analysis EMEA)

Actual change from baseline in FEV1 percent of predicted across 3 treatment courses among all subjects (superiority analysis) (Analysis FDA)
Secondary Outcome(s)
Secondary ID(s)
2007-004277-26-BE
GS-US-205-0110
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey